drugset

drugset / Trial / NCT07206758

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

NCT07206758 ↗

Phase 1 Recruiting 10 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd

NaSingle-groupOpen-labelTreatment

Summary

Evaluate the safety and tolerance of multiple subcutaneous injections of SHR-2173 in ITP patients

Timeline

Start: 2025-11-12
Primary completion: 2026-06
Completion: 2026-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR-2173	Unknown	—	Subcutaneous

Indications